Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Cash & Equivalents for 8 consecutive years, with $64.4 million as the latest value for Q3 2024.
- Quarterly Cash & Equivalents rose 31.32% to $64.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $64.4 million through Sep 2024, up 31.32% year-over-year, with the annual reading at $74.0 million for FY2023, 52.37% down from the prior year.
- Cash & Equivalents hit $64.4 million in Q3 2024 for Solid Biosciences, down from $95.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $268.5 million in Q1 2021 to a low of $24.8 million in Q3 2020.
- Historically, Cash & Equivalents has averaged $106.2 million across 5 years, with a median of $95.9 million in 2024.
- Biggest five-year swings in Cash & Equivalents: plummeted 73.91% in 2020 and later skyrocketed 401.73% in 2021.
- Year by year, Cash & Equivalents stood at $155.1 million in 2020, then fell by 23.17% to $119.1 million in 2021, then skyrocketed by 30.43% to $155.4 million in 2022, then crashed by 52.37% to $74.0 million in 2023, then decreased by 13.0% to $64.4 million in 2024.
- Business Quant data shows Cash & Equivalents for SLDB at $64.4 million in Q3 2024, $95.9 million in Q2 2024, and $117.6 million in Q1 2024.